Recordati SpA (FRA:RER1) 3-Year EPS without NRI Growth Rate : 2.60% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Recordati SpA 3-Year EPS without NRI Growth Rate?

Recordati SpA's EPS without NRI for the three months ended in Dec. 2023 was €0.41.

During the past 12 months, Recordati SpA's average EPS without NRI Growth Rate was 8.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 2.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Recordati SpA was 44.90% per year. The lowest was -1.40% per year. And the median was 13.10% per year.

Competitive Comparison of Recordati SpA's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Recordati SpA's 3-Year EPS without NRI Growth Rate falls into.

Recordati SpA 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Recordati SpA (FRA:RER1) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Recordati SpA 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Recordati SpA's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (FRA:RER1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (FRA:RER1) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (FRA:RER1) Headlines

No Headlines